{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T23:12:39Z","timestamp":1790118759944,"version":"4.0.1"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T00:00:00Z","timestamp":1706832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s10067-024-06891-x","type":"journal-article","created":{"date-parts":[[2024,2,2]],"date-time":"2024-02-02T01:02:16Z","timestamp":1706835736000},"page":"1183-1188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Risk of gout flare after medication: prescription symmetry sequence analysis"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7420-1572","authenticated-orcid":false,"given":"Shih-Wei","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing-Fang","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Hung","family":"Kuo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiu-Shong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Fu","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,2]]},"reference":[{"key":"6891_CR1","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1002\/sim.4780071110","volume":"7","author":"H Petri","year":"1988","unstructured":"Petri H, de Vet HC, Naus J, Urquhart J (1988) Prescription sequence analysis: a new and fast method for assessing certain adverse reactions of prescription drugs in large populations. Stat Med 7:1171\u20131175","journal-title":"Stat Med"},{"key":"6891_CR2","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1097\/00001648-199609000-00005","volume":"7","author":"J Hallas","year":"1996","unstructured":"Hallas J (1996) Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology 7:478\u2013484","journal-title":"Epidemiology"},{"key":"6891_CR3","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s10654-017-0281-8","volume":"32","author":"EC Lai","year":"2017","unstructured":"Lai EC, Pratt N, Hsieh CY, Lin SJ, Potteg\u00e5rd A, Roughead EE et al (2017) Sequence symmetry analysis in pharmacovigilance and pharmacoepidemiologic studies. Eur J Epidemiol 32:567\u2013582","journal-title":"Eur J Epidemiol"},{"key":"6891_CR4","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1016\/j.sapharm.2021.08.003","volume":"18","author":"EJ Morris","year":"2022","unstructured":"Morris EJ, Hollmann J, Hofer AK, Bhagwandass H, Oueini R, Adkins LE et al (2022) Evaluating the use of prescription sequence symmetry analysis as a pharmacovigilance tool: a scoping review. Res Social Adm Pharm 18:3079\u20133093","journal-title":"Res Social Adm Pharm"},{"key":"6891_CR5","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1016\/j.jamda.2021.06.035","volume":"23","author":"Y Chen","year":"2022","unstructured":"Chen Y, Huang ST, Hsu TC, Peng LN, Hsiao FY, Chen LK (2022) Detecting suspected prescribing cascades by prescription sequence symmetry analysis of nationwide real-world data. J Am Med Dir Assoc 23:468\u2013474","journal-title":"J Am Med Dir Assoc"},{"key":"6891_CR6","doi-asserted-by":"publisher","first-page":"1843","DOI":"10.1016\/S0140-6736(21)00569-9","volume":"397","author":"N Dalbeth","year":"2021","unstructured":"Dalbeth N, Gosling AL, Gaffo A, Abhishek A (2021) Gout Lancet 397:1843\u20131855","journal-title":"Gout Lancet"},{"key":"6891_CR7","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.1056\/NEJMcp2203385","volume":"387","author":"TR Mikuls","year":"2022","unstructured":"Mikuls TR (2022) Gout. N Engl J Med 387:1877\u20131887","journal-title":"N Engl J Med"},{"key":"6891_CR8","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0950-3579(05)80295-X","volume":"5","author":"JT Scott","year":"1991","unstructured":"Scott JT (1991) Drug-induced gout. Baillieres Clin Rheumatol 5:39\u201360","journal-title":"Baillieres Clin Rheumatol"},{"key":"6891_CR9","first-page":"679","volume":"56","author":"C Ben Salem","year":"2017","unstructured":"Ben Salem C, Slim R, Fathallah N, Hmouda H (2017) Drug-induced hyperuricaemia and gout. Rheumatology (Oxford) 56:679\u2013688","journal-title":"Rheumatology (Oxford)"},{"key":"6891_CR10","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1002\/pds.1736","volume":"18","author":"I Tsiropoulos","year":"2009","unstructured":"Tsiropoulos I, Andersen M, Hallas J (2009) Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf 18:483\u2013491","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6891_CR11","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1016\/S2213-8587(18)30029-9","volume":"6","author":"B Waldman","year":"2018","unstructured":"Waldman B, Ansquer JC, Sullivan DR, Jenkins AJ, McGill N, Buizen L et al (2018) Effect of fenofibrate on uric acid and gout in type 2 diabetes: a post-hoc analysis of the randomised, controlled FIELD study. Lancet Diabetes Endocrinol 6:310\u2013318","journal-title":"Lancet Diabetes Endocrinol"},{"key":"6891_CR12","doi-asserted-by":"publisher","first-page":"1855","DOI":"10.1097\/00004872-200110000-00021","volume":"19","author":"G W\u00fcrzner","year":"2001","unstructured":"W\u00fcrzner G, Gerster JC, Chiolero A, Maillard M, Fallab-Stubi CL, Brunner HR et al (2001) Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout. J Hypertens 19:1855\u20131860","journal-title":"J Hypertens"},{"key":"6891_CR13","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1002\/acr.24180","volume":"72","author":"JD FitzGerald","year":"2020","unstructured":"FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt G, Abeles AM et al (2020) 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care Res (Hoboken) 72:744\u2013760","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6891_CR14","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1002\/pds.5252","volume":"30","author":"LC Lund","year":"2021","unstructured":"Lund LC, H\u00f8jlund M, Henriksen DP, Hallas J, Kristensen KB (2021) Sodium-glucose cotransporter-2 inhibitors and the risk of gout: a Danish population based cohort study and symmetry analysis. Pharmacoepidemiol Drug Saf 30:1391\u20131395","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"6891_CR15","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1007\/s10067-023-06647-z","volume":"42","author":"DT Wood","year":"2023","unstructured":"Wood DT, Waterbury NV, Lund BC (2023) Sodium glucose cotransporter 2 inhibitors and gout risk: a sequence symmetry analysis. Clin Rheumatol 42:2469\u20132475","journal-title":"Clin Rheumatol"},{"key":"6891_CR16","doi-asserted-by":"publisher","first-page":"2673","DOI":"10.3390\/nu13082673","volume":"13","author":"JR Hu","year":"2021","unstructured":"Hu JR, Yeh HC, Mueller NT, Appel LJ, Miller ER 3rd, Maruthur NM et al (2021) Effects of a behavioral weight loss intervention and metformin treatment on serum urate: results from a randomized clinical trial. Nutrients 13:2673","journal-title":"Nutrients"},{"key":"6891_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1093\/rheumatology\/kex363","volume":"57","author":"SW Niu","year":"2018","unstructured":"Niu SW, Chang KT, Lin HY, Kuo IC, Chang YH, Chen YH et al (2018) Decreased incidence of gout in diabetic patients using pioglitazone. Rheumatology (Oxford) 57:92\u201399","journal-title":"Rheumatology (Oxford)"},{"key":"6891_CR18","doi-asserted-by":"publisher","first-page":"151","DOI":"10.3109\/07435800.2012.745128","volume":"38","author":"E Kutoh","year":"2013","unstructured":"Kutoh E, Hori T (2013) Effect of pioglitazone on serum uric acid levels in newly diagnosed, drug-na\u00efve patients with type 2 diabetes. Endocr Res 38:151\u2013159","journal-title":"Endocr Res"},{"key":"6891_CR19","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1002\/pds.3417","volume":"22","author":"IA Wahab","year":"2013","unstructured":"Wahab IA, Pratt NL, Wiese MD, Kalisch LM, Roughead EE (2013) The validity of sequence symmetry analysis (SSA) for adverse drug reaction signal detection. Pharmacoepidemiol Drug Saf 22:496\u2013502","journal-title":"Pharmacoepidemiol Drug Saf"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06891-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-024-06891-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-024-06891-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,22]],"date-time":"2024-02-22T06:14:04Z","timestamp":1708582444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-024-06891-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,2]]},"references-count":19,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["6891"],"URL":"https:\/\/doi.org\/10.1007\/s10067-024-06891-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,2]]},"assertion":[{"value":"4 October 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 January 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 February 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}